103 search results
- Current search:
- Movement Disorders
- Reset
Primary tabs
- Cochrane Evidence (active tab)
- Resources
- Handbooks & Manuals
- Training & Workshops
- News
- All Cochrane sites
-
Cochrane EvidencePublished 14 Apr 2017
Use of topiramate for the treatment of essential tremor
Review question The authors of this review tried to assess the effectiveness and safety of topiramate in people with essential tremor. Background Essential tremor is a type of uncontrollable shaking or trembling of parts of the body. Although it is not harmful in terms of its effect on life expectancy, it generally gets worse and may be disabling. ... -
TitlePublished 9 Apr 2017
Singing for people with Parkinson’s Disease
Movement Disorders Group J. Yoon Irons Title Wednesday, April 5, 2017 ... -
Cochrane EvidencePublished 20 Mar 2017
Benzodiazepines for restless legs syndrome
Background Restless legs syndrome (RLS) is a common and distressing disease affecting 5% to 15% of the population. Many physicians are still unaware of the disease and do not recognize its symptoms. This disease can affect sleep significantly, impairing quality of life. There is a need for safe and effective treatment for RLS. Current treatments include ... -
TitlePublished 25 Dec 2016
Robot-assisted gait training for Parkinson's disease
Movement Disorders Group Yuma Sonoda Title Wednesday, December 21, 2016 ... -
Cochrane EvidencePublished 21 Dec 2016
Virtual reality technology as a useful tool for rehabilitation in Parkinson's disease
Review question The purpose of this review was to determine the effectiveness of virtual reality (VR) exercise interventions for rehabilitation in Parkinson’s disease (PD). We aimed to investigate whether VR exercise resulted in greater improvements compared to 1) active control interventions, and 2) passive control interventions, on gait, balance, ... -
Cochrane EvidencePublished 16 Nov 2016
Trihexyphenidyl for dystonia in cerebral palsy
Protocol: To evaluate the effects of trihexyphenidyl on the World Health Organisation's (WHO) International Classification of Functioning, Disability and Health (ICF) domains of impairment, activity, and participation in individuals with dystonic cerebral palsy. To assess the type and incidence of adverse effects from the use of trihexyphenidyl ... -
TitlePublished 6 Nov 2016
Incretin-based therapies for Parkinson's disease
Movement Disorders Group Caroline Mulvaney Title Friday, November 4, 2016 ... -
Cochrane EvidencePublished 28 Oct 2016
Botulinum toxin for drooling in Parkinson’s disease
Protocol: Primary objective: to assess the efficacy of botulinum toxin treatment to reduce or eliminate drooling in adults with Parkinson’s disease. Secondary objective: to assess the adverse effects of botulinum toxin treatment for drooling in adults with Parkinson’s disease. -
Cochrane EvidencePublished 26 Oct 2016
A comparison of botulinum toxin type A versus botulinum toxin type B for involuntary positioning of the head, or cervical dystonia
The review question We reviewed the evidence about the effect of botulinum toxin type A (BtA) compared to botulinum toxin type B (BtB) in people with involuntary positioning of the head, or cervical dystonia. This is an update of a previous Cochrane Review and we assessed the effectiveness (reduction in severity, disability and pain) and safety of ... -
Cochrane EvidencePublished 20 Oct 2016
Use of pregabalin for the treatment of essential tremor
Review question The authors of this review tried to assess the effectiveness and safety of pregabalin in people with essential tremor. Backgound Essential tremor is the most common movement disorder. Although benign in terms of its effect on life expectancy, it is typically progressive and potentially disabling. Treatment consists primarily of pharmacological ...
